MedTrace Logo

PIERS and BIS, sFIT:PIGF, Adrenomedullin

NCT02578810 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2026-04-23

No results posted yet for this study

Summary

Pre-eclampsia, more than being proteinuric gestational hypertension alone, is a state of exaggerated systemic inflammation and remains a leading direct cause of maternal morbidity and mortality worldwide.1 Standardization of antenatal and postnatal assessment and surveillance of pre-eclampsia with protocols that recognize the systemic inflammatory model of preeclampsia have been associated with reduced maternal morbidity.

Conditions

  • Eclampsia

Sponsors & Collaborators

  • University of Malaya

    collaborator OTHER

  • Suez Canal University

    lead OTHER

Principal Investigators

  • Ashraf Dahaba, MD · Guest Professor

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02578810 on ClinicalTrials.gov